BTK and asthma: Novel therapies, including anti-IgE monoclonal antibodies (e.g., Omalizumab), tyrosine kinase inhibitors (e.g., imatinib, avapritinib), BTK inhibitors (e.g., Ibrutinib), and anti-KIT antibodies (e.g., barzolvolimab), offer promising strategies for treating conditions such as severe asthma, chronic urticaria, and systemic mastocytosis.